Objective: Nebivolol is a selective β 1-adrenergic receptor blocker possessing an ancillary
vasodilating effect. The objective of the present study was to study the haemodynamic and …

Endothelial dysfunction is a systemic pathological state of the endothelium characterized by
a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired …

Although their specific mechanisms of action are incompletely understood, beta blockers are
most likely lower blood pressure and provide target organ protection by several different …

BACKGROUND: Nebivolol is a β1-selective β-blocker with NO-mediated vasodilatory
properties, approved in the United States for the treatment of stage I–II hypertension …

Nebivolol, a vasodilatory β1‐blocker, may be well suited for the hemodynamics of the
younger hypertensive patient. In this 8‐week trial, 18‐to 54‐year‐olds with a diastolic blood …

This aim of this study was to evaluate the presence of endothelial dysfunction in patients
with primary hypertension and to determine the usefulness of nebivolol, a selective β …

CONTEXT AND OBJECTIVES: Assessment of central blood pressure (BP) has grown
substantially over recent years because evidence has shown that central BP is more …

Abstract β-Adrenoceptor antagonists (β-blockers) have historically been considered an
effective and safe option for first-line treatment of hypertension. However, very recently, it …

Abstract Introduction: Hypertension,“The silent killer” is a multifactorial disorder which is
asymptomatic and if left untreated leads to lethal complications. Nebivolol is a third …

Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile
dysfunction, vascular disease, and diabetes mellitus. This review investigated the data …